{
    "clinical_study": {
        "@rank": "11587", 
        "arm_group": [
            {
                "arm_group_label": "GLPG1205 single dose", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose of GLPG1205 suspension - ascending doses"
            }, 
            {
                "arm_group_label": "Placebo single dose", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single oral dose of placebo suspension"
            }, 
            {
                "arm_group_label": "GLPG1205 multiple doses", 
                "arm_group_type": "Experimental", 
                "description": "Multiple oral doses of GLPG1205 suspension - ascending doses"
            }, 
            {
                "arm_group_label": "Placebo multiple doses", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Multiple oral doses of placebo suspension"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this First-in-Human study is to evaluate the safety and tolerability after\n      single ascending oral doses of GLPG1205 given to healthy male subjects, compared to placebo.\n      Also, the safety and tolerability of multiple ascending oral doses of GLPG1205 given to\n      healthy male subjects daily for 14 days compared to placebo, will be evaluated.\n\n      Furthermore, during the course of the study after single and multiple oral dose\n      administrations, the amount of GLPG1205 present in the blood and urine (pharmacokinetics) as\n      well as the receptor occupancy by GLPG1205 in blood samples (pharmacodynamics) will be\n      characterized compared to placebo.\n\n      Also, the potential of cytochrome P450 (CYP)3A4 induction after repeated dosing with\n      GLPG1205 will be explored."
        }, 
        "brief_title": "First-in-Human Single and Multiple Dose of GLPG1205", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male, age 18-50 years\n\n          -  BMI between 18-30 kg/m2\n\n        Exclusion Criteria:\n\n          -  Any condition that might interfere with the procedures or tests in this study\n\n          -  Drug or alcohol abuse\n\n          -  Smoking"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887106", 
            "org_study_id": "GLPG1205-CL-101"
        }, 
        "intervention": [
            {
                "arm_group_label": "GLPG1205 single dose", 
                "description": "Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg", 
                "intervention_name": "GLPG1205 single ascending doses, oral suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo single dose", 
                "description": "Single dose, oral suspension matching placebo", 
                "intervention_name": "Placebo single ascending doses, oral suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "GLPG1205 multiple doses", 
                "description": "Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg", 
                "intervention_name": "GLPG1205, multiple ascending doses, oral suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo multiple doses", 
                "description": "Multiple doses, daily for 14 days, oral suspension matching placebo", 
                "intervention_name": "Placebo, multiple ascending doses, oral suspension", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerp", 
                    "country": "Belgium"
                }, 
                "name": "SGS LSS Clinical Pharmacology Unit Antwerp"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "4", 
        "official_title": "Randomized, Double-blind, Placebo-controlled, Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1205 in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Galapagos NV", 
            "last_name": "Fr\u00e9d\u00e9ric Vanhoutte, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate the safety and tolerability of GLPG1205 in comparison with placebo after a single oral dose in healthy subjects in terms of adverse events, physical examinations, vital signs, ECG and lab assessments", 
                "measure": "Safety and tolerability after single dose", 
                "safety_issue": "Yes", 
                "time_frame": "Between screening and 7-10 days after the last dose"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG1205 in comparison with placebo after multiple oral doses daily for 14 days in healthy subjects in terms of adverse events, physical examinations, vital signs, ECG and lab assessments", 
                "measure": "Safety and tolerability after multiple doses", 
                "safety_issue": "Yes", 
                "time_frame": "Between screening and 7-10 days after the last dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887106"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To characterize the amount of GLPG1205 in plasma and urine over time - pharmacokinetics (PK) - after a single oral dose in healthy subjects", 
                "measure": "The amount of GLPG1205 in plasma and urine over time after a single oral dose", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 predose and 48 hours post dose"
            }, 
            {
                "description": "To characterize the amount of GLPG1205 in plasma and urine over time - pharmacokinetics (PK) - after multiple oral doses in healthy subjects", 
                "measure": "The amount of GLPG1205 in plasma and urine over time after multiple oral doses", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 predose and Day 16 (48 hours after the last dose)"
            }, 
            {
                "description": "To assess the potential of CYP3A4 induction after repeated dosing with GLPG1205 by means of the ratio of 6-b-hydroxycortisol/cortisol in urine", 
                "measure": "Ratio of 6-b-hydroxycortisol/cortisol in urine", 
                "safety_issue": "No", 
                "time_frame": "Twelve hours before dosing on Day 1 and Day 14"
            }, 
            {
                "description": "To characterize the pharmacodynamics (PD) of GLPG1205 by means of receptor occupancy by GLPG1205 on blood cells after a single oral dose in healthy subjects", 
                "measure": "Receptor occupancy by GLPG1205 on blood cells after a single dose", 
                "safety_issue": "No", 
                "time_frame": "Day 1 predose up to 24 hours post dose"
            }, 
            {
                "description": "To characterize the pharmacodynamics (PD) of GLPG1205 by means of receptor occupancy by GLPG1205 on blood cells after multiple oral doses in healthy subjects", 
                "measure": "Receptor occupancy by GLPG1205 on blood cells after multiple doses", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 14, predose up to 24 hours post dose"
            }
        ], 
        "source": "Galapagos NV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galapagos NV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}